At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 142 enrolled
Drug / intervention
HMI-115 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of HMI-115 in Women With Moderate to Severe Endometriosis-Associated Pain Over a 12-Week Treatment Period
In Brief
A Phase 2 clinical trial evaluating HMI-115 and Placebo for Endometriosis. Completed, enrolled 142 participants across 5 sites in 3 countries.
Detailed Summary
This study is designed to evaluate the safety and efficacy of HMI-115 compared to placebo over a 12 weeks period on subjects with moderate to severe endometriosis-associated pain.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEndometriosis
CountriesChina, Poland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartOct 2021
First PostedNov 2021
Primary CompletionSep 2024
Study CompletionMar 2025
TodayJul 2026
First PostedNov 1, 2021
Enrollment StartOct 11, 2021
Primary CompletionSep 26, 2024
Study CompletionMar 19, 2025
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 4.7 years ago
Interventions
HMI-115drug
HMI-115 is human monoclonal antibody
Placebodrug
Placebo